Searchable abstracts of presentations at key conferences in endocrinology
Previous issue | Volume 20 | ECE2009 | Next issue

11th European Congress of Endocrinology

Poster Presentations

Endocrine tumours and neoplasia

ea0020p172 | Endocrine tumours and neoplasia | ECE2009

Manifestations of Hyperprolactinoma and its Management by Bromocriptine and Cabergoline

Qari Faiza

This is a prospective study analyzing gender differences in the presentation of hyperprolactinemia as well as the efficacy and tolerance to cabergoline and bromocriptine. Thirty-six patients (23 women, 13 men) were recruited and divided into two groups; Group One received bromocriptine and Group Two received cabergoline for three months. The prolactin level was measured before and after treatment in both groups. Galactorrhea and infertility were more common symptoms in women; ...

ea0020p173 | Endocrine tumours and neoplasia | ECE2009

Von-Hippel-Lindau disease: clinical report

Santos Jacinta , Paiva Isabel , Martinho Mariana , Vieira Alexandra , Vieira Diniz , Cunha Lurdes , Martinho Fernando , Carvalheiro Manuela

Background: Von-Hippel-Lindau disease (VHL) is a rare (1/36.000 newborns), autosomal, dominant inherited tumour syndrome. A germline mutation in VHL tumour suppressor gene predisposes carriers to tumours in multiple organs. In the presence of positive family history, it can be diagnosed clinically in a patient with at least one typical VHL tumour.Clinical report: In December 2007, a 34 years-old women presented with palpitations and tachycardia, but norm...

ea0020p174 | Endocrine tumours and neoplasia | ECE2009

Assessment of interferon α-2a in pharmaceutical formulations by liquid chromatography methods

Dalmora Sergio Luiz , da Silva Lucelia Magalhaes , Zimmermann Estevan Sonego , Lana Aline Jacobi Dalla , Sangoi Maximiliano da Silva , D'Avila Felipe Bianchini

The recombinant human interferon α-2a (rhIFN α-2a) is a cytokine with antiviral, antiproliferative and immunomodulatory properties, indicated for the treatment of hepatitis B and C and leukemias. The rhIFN α-2a consists of a 165–166 amino acids with molecular mass of 19.5 kDa. The aim of this work was to develop and validate the reversed-phase (RP-LC) and size-exclusion (SE-LC) liquid chromatography methods for the physico-chemical characterization of rhIFN...

ea0020p175 | Endocrine tumours and neoplasia | ECE2009

Pregnancy and childbirth in active acromegaly patient treated with long acting somatostatin analog

Nechaeva Olga , Pokramovich Julia , Dreval Alexander

In 24 years old woman in March 2007 was diagnosed acromegaly (somatoprolactinoma) an active phase, hyperprolactinemia. Manifestations: rugged features, amenorrhea, galactorrhea, fasting GH – 144 ng/ml (N<10 ng/ml), IGF-1 – 586 ng/ml (N 48–450 ng/ml), PRL – 6726 mU/l (N 40–530 mU/l). According to pituitary MRT a tumor volume was 14.4 cm3, with supra- and infrasella growth. She was operated in May 2007: transnal transs...

ea0020p176 | Endocrine tumours and neoplasia | ECE2009

Ectopic growth hormone-releasing hormone secretion by a neuroendocrine tumor causing acromegaly: long-term follow-up results

Ozbey Nese Colak , Kapran Yersu , Bozbora Alp , Erbil Yesim , Tascioglu Cemil , Asa Silvia L

Less than 1% cases of acromegaly is caused by ectopic secretion of growth hormone releasing hormone (GHRH).A 25-year-old woman was admitted to the hospital, with iron deficiency anemia, acromegaly and a 6×6 cm mass in infrahepatic location near to the pancreatic head. Sellar magnetic resonance (MR) imaging indicated pituitary enlargement without obvious evidence of a pituitary adenoma. The patients underwent abdominal exploration. Histopathological ...

ea0020p177 | Endocrine tumours and neoplasia | ECE2009

Misleading, difficult and lucky path towards a diagnosis in a medullary thyroid carcinoma case

Parisi Gaetana , De Remigis Pierluigi , Vianale Luigi , Ciccarone Elisabetta

MTC represents still a diagnostic challenge in thyroidology. A case is here reported with some misleading signs that was finally solved with a calcitonin assay.A 50 years women was referred for a thyroid nodule incidentally discovered at echography in the right lobe; it appeared round, hypoechoic, without alo sign, well-definite edges, with a diameter of 7 mm. At the first evaluation with echocolordoppler there was no appearance of intralesion vasculariz...

ea0020p178 | Endocrine tumours and neoplasia | ECE2009

Predictive value of interleukin-10 promoter genotypes and haplotypes in determining the susceptibility to nephropathy in type 2 diabetes patients

Mtiraoui Nabil , Ezzidi Intissar , Chieb Molka , Kacem Maha , Mahjoub Touhami , Almawi WassimY

Background: The IL-10 promoter polymorphisms −1082G/A, −819C/T, and −592C/A have been consistently associated with type 2 diabetes (T2DM). We examined whether these polymorphisms variants are also associated with progression of diabetic nephropathy (DN).Methods: These promoter variants were genotyped in 917 T2DM patients comprising 515 DN patients and 402 control patients without nephropathy (DWN), together with 748 non-diabetic control...

ea0020p179 | Endocrine tumours and neoplasia | ECE2009

AIP immunostaining is increased with lanreotide therapy in individuals with acromegaly and predicts changes in IGF-1 levels in female patients

Chahal Harvinder , Ansorge Olaf , Karavitaki Niki , Carlsen Eivind , Wass John , Grossman Ashley , Korbonits Marta

Background: Recently mutations in the aryl hydrocarbon receptor interacting protein (AIP) gene have been found to occur in familial and sporadic somatotroph adenomas. These tumours tend to respond less well to somatostatin analogues, are diagnosed at an earlier age and behave more aggressively. AIP is expressed in sporadic somatotroph adenomas (Leontiou, JCEM, 2008).Aim: To evaluate the change in AIP immunostaining in sporadic acromegaly patients treated...

ea0020p180 | Endocrine tumours and neoplasia | ECE2009

Papillary thyroid carcinoma associated with thyroid autoimmunity: clinical and molecular characterization

Muzza Marina , Colombo Carla , Perrino Michela , Rossi Stefania , Cirello Valentina , Beck-Peccoz Paolo , Fugazzola Laura

It is still debated if the coexistence of papillary thyroid cancer (PTC) with a thyroid autoimmune process is associated with a better or worst outcome. Moreover, though a direct relationship between oncogenes and the activation of a pro-inflammatory program has been documented, the genetic background of PTCs with associated autoimmunity is not known.Aim of the present study was to to investigate the clinical and molecular features of PTCs associated or ...

ea0020p181 | Endocrine tumours and neoplasia | ECE2009

Steroidogenic factor 1 – a valuable diagnostic and prognostic tool in patients with adrenocortical carcinoma

Sbiera Silviu , Schmull Sebastian , Voelker Hans-Ullrich , Kraus Luitgard , Beuschlein Felix , Willenberg Holger , Hahner Stefanie , Allolio Bruno , Fassnacht Martin

Objectives: No immunohistochemical marker has yet been established to reliably differentiate adrenocortical tumors from other adrenal masses (e.g. metastases). Thus, a panel of several markers like melan A and inhibin is currently used for this purpose, but suffers from limited diagnostic accuracy. We hypothesized that expression of steroidogenic factor 1 (SF-1), a nuclear transcription factor involved in adrenal development and steroidogenesis, might hold significant diagnost...

ea0020p182 | Endocrine tumours and neoplasia | ECE2009

Endocrine gland-derived vascular endothelial growth factor and its receptors in adrenocortical carcinoma

Sbiera Silviu , Kuehner Dorothee , Wortmann Sebastian , Adam Patrick , Voelker Hans-Ullrich , Kraus Luitgard , Beyer Melanie , Quinkler Markus , Willenberg Holger , Weismann Dirk , Hahner Stefanie , Allolio Bruno , Fassnacht Martin

Objectives: Endocrine gland-derived vascular endothelial growth factor (EG-VEGF; also termed prokineticin-1) has been identified as a mitogen preferable for the endothelium of steroidogenic glands (1). EG-VEGF and its receptors (prokineticin receptors 1 and 2; PKR1 and 2) are highly expressed in the normal adrenal gland and an autocrine mitogenic loop has been proposed (2). Therefore, we investigated the expression of EG-VEGF and its receptors in adrenocortical carcinoma (ACC)...

ea0020p183 | Endocrine tumours and neoplasia | ECE2009

Differential expression of microRNAs in human parathyroid carcinomas compared with normal parathyroid tissue

Corbetta Sabrina , Vaira Valentina , Guarnieri Vito , Scillitani Alfredo , Eller-Vainicher Cristina , Vicentini Leonardo , Chiodini Jacopo , Bisceglia Michele , Beck-Peccoz Paolo , Bosari Silvano , Spada Anna

Parathyroid carcinoma is a rare cause of primary hyperparathyroidism. Though the loss of the oncosuppressor HRPT2 gene product, parafibromin, has been involved in the hyperparathyroidism-jaw tumor syndrome and in a consistent set of sporadic parathyroid carcinomas, parathyroid carcinogenesis remains obscure. MicroRNAs (miRNAs) are a new class of small, non-coding RNAs implicated in embryonic development and cancer. A deregulated miRNA can induce the aberrant expression ...

ea0020p184 | Endocrine tumours and neoplasia | ECE2009

Recombinant human thyrotropin in follow-up of patients with differentiated thyroid cancer

Podoba Jan

Background: Despite good prognosis patients with previously treated well-differentiated thyroid cancer (DTC) require lifelong monitoring for recurrent disease. The diagnostic value of radioiodine whole body scanning and serum thyroglobulin (Tg) measurement is most accurate during thyroid stimulating hormone (TSH) stimulation. The introduction of recombinant human TSH (rhTSH)-stimulated testing offers the possibility to avoid hormone withdrawal associated with the morbidity of ...

ea0020p185 | Endocrine tumours and neoplasia | ECE2009

Estradiol influences somatostatin receptor expression and potentiates the effects of SOM230 on prostate cells

Rossi Valentina , Bellastella Giuseppe , Visconti Daniela , Abbondanza Ciro , Maione Luigi , Bellastella Antonio , Agostino Sinisi Antonio

Somatostatin (SS) receptors (SSR) expression may be modulated by estrogens in breast cancer cells. Aim of this study was to evaluate the effects of estradiol (E2) on SSR levels in prostate epithelial cells (PEC).Methods: We investigated the effects of E2 and SS-analogue SOM230 combined treatment on two PEC lines: EPN that expresses both ERalfa and beta and CPEC, showing no ERalfa and very low ERbeta expression. Cells starved in red ...

ea0020p186 | Endocrine tumours and neoplasia | ECE2009

mTOR inhibition influences cell viability of medullary thyroid carcinoma primary cultures

Filieri Carlo , Minoia Mariella , Tagliati Federico , Mole Daniela , Buratto Mattia , Margutti Angelo , degli Uberti Ettore , Chiara Zatelli Maria

Effective medical therapy for persistent/recurrent medullary thyroid carcinoma (MTC) is not available, yet. Everolimus (RAD001) is a Rapamycin derivative, a potent mTOR pathway inhibitor. RAD001 has been employed in several clinical studies demonstrating antiproliferative and apoptotic effects in human tumors, both in vitro and in vivo, also in combination with somatostatin analogs. The aim of our study was to investigate the antiproliferative effects of RAD001 i...

ea0020p187 | Endocrine tumours and neoplasia | ECE2009

Presence and potential pathophysiological relevance of GOAT, the ghrelin O-acylation enzyme, in human pituitary tumors

Quintero Ana , Martinez-Fuentes Antonio J , Dieguez Carlos , Benito-Lopez Pedro , Leal Alfonso , Webb Susan , Malagon Maria M , Luque Raul M , Castano Justo P

Ghrelin was isolated from stomach by its ability to stimulate growth hormone (GH) release through the GH-secretagogue receptor (GHS-R1a). However, ghrelin/GHS-R expression in multiple tissues and tumor types suggested additional roles for this tandem. Ghrelin, a 28-aminoacid peptide, requires a unique O-acylation at its Ser-3 residue to bind GHS-R1a and release GH. Conversely, unacylated ghrelin (UAG), initially considered inactive, seems to play distinct metabolic role...

ea0020p188 | Endocrine tumours and neoplasia | ECE2009

Efficacy of repeat surgery in patients with recurrent adrenocortical cancer

Daffara Fulvia , De Francia Silvia , Ardito Arianna , Zaggia Barbara , Fiori Cristian , Angeli Alberto , Scarpa Roberto , Porpiglia Francesco , Perotti Paola , Berruti Alfredo , Terzolo Massimo

The optimal treatment of recurrent adrenocortical cancer (ACC) remains to be established since there are discrepant opinions on the value of repeat surgery. We did a retrospective analysis of the outcome of patients who were referred to our units from 1988 to 2006 for a recurrence of ACC, which occurred 2–83 years after radical removal of the tumor. In that period, the treatment policy of ACC recurrence differed among our units, since oncologists were more accustomed to u...

ea0020p189 | Endocrine tumours and neoplasia | ECE2009

Tumor/liver standardized uptake values ratio <1.8 on FDG-PET has a high negative predicitive value to rule-out malignancy in patients with incidentally identified non-secreting adrenal tumours

Taieb David , Tessonnier Laurent , Sebag Frederic , Morange Isabelle , De Micco Catherine , Conte-Devolx Bernard , Henry Jean-Francois , Mundler Olivier

Purpose: The widespread use of high resolution cross-sectional imaging such as computer tomography (CT) and magnetic resonance imaging (MRI) for the investigation of the abdomen is associated with an increasing detection of incidental adrenal masses. 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) has proved to be an efficient tool in the diagnosis and follow-up of malignancies. We evaluated the ability of FDG-PET to distinguish benign from malignant adrenal mass...

ea0020p190 | Endocrine tumours and neoplasia | ECE2009

Serum chromogranin A assay in the biological diagnosis of pheochromocytomas and/or paragangliomas: results in 146 patients

d'Herbomez Michele , Bauters Catherine , Caron Philippe , Do Cao Christine , Pigny Pascal , Leteurtre Emmanuelle , Carnaille Bruno , Wemeau Jean-Louis

The biological diagnosis of pheochromocytoma (P) and/or paraganglioma (Pgg) relies on the identification of excessive secretion of the metanephrines. Chomogranin A (CgA) is a general indicator of neuroendocrine tumours that is highly expressed in P and correlate with tumour mass and secretory activity. The CgA test could be indicated as a useful test in patients with false positive metanephrines results. The aim of our prospective bi-centre study, is to evaluate the performanc...

ea0020p191 | Endocrine tumours and neoplasia | ECE2009

Clinical features and outcome of thyroid lymphoma: the Auvergne registry

Roche Beatrice , Solmon Caroline , Robu Elena , Desbiez Francoise , Thieblot Philippe , Tauveron Igor

Introduction: Thyroid lymphoma is a rare thyroid disease, occurring mostly in the elderly. We report a series of 13 cases from a single centre.Material and methods: Among our regional registry (1294 cases of thyroid cancer), we report 16 cases of thyroid lymphoma (with sufficient data on follow up for 13).Results: Mean age was 68.3 years (range 38–85) and included 12 women for 1 man. Nine patients also presented with Hashimoto...

ea0020p192 | Endocrine tumours and neoplasia | ECE2009

The comparison of serum endostatin levels between patients with metastatic and non-metastatic well differentiated thyroid cancer

Klubo-Gwiezdzinska Joanna , Roman Junik , Ewa Kopczynska

Tumor growth is limited by its neoangiogenesis, which is dependent on dynamic balance beetween it’s activators and inhibitors. One of the most important antiangiogenic factor is endostatin. Therefore we hypothesized, that serum endostatin concentration would differ between patients with metastatic and non-metastatic thyroid cancer, with multinodular goiter and healthy subjects. We also hypothesized that endogenous TSH stimulation would effect serum endostatin level.<p...

ea0020p193 | Endocrine tumours and neoplasia | ECE2009

Effectiveness and safety of combined therapy with low dose ketoconazole and cabergoline in patients with Cushing’s disease partially responsive to monotherapy with cabergoline

Pivonello Rosario , De Leo Monica , De Martino MariaCristina , Cozzolino Alessia , Auriemma Renata S , Galdiero Mariano , Lombardi Gaetano , Colao Annamaria

The first-line treatment of Cushing’s disease is surgery, although it is effective in inducing a long-term remission in around 50% of patients with Cushing’s disease (CD). Nowadays, no pituitary tumor-directed medical treatment is available with the exception of cabergoline, which has been recently demonstrated to control cortisol secretion without major side effects in around 40% of patients with Cushing’s disease. Cabergoline has been recently demonstrated to ...

ea0020p194 | Endocrine tumours and neoplasia | ECE2009

Impact of surgery on clinical outcome in patients with recurrence of adrenocortical carcinoma

Erdogan Ilknur , Hahner Stefanie , Johanssen Sarah , Fenske Wiebke , Quinkler Marcus , Willenberg Holger S , Beuschlein Felix , Brix David , Allolio Bruno , Fassnacht Martin

Introduction: The role of surgery for recurrent ACC is not well defined. Therefore, we used the German ACC Registry to evaluate treatment modalities after first recurrence in patients amenable to surgery.Methods: Patients with recurrence after radical resection and follow-up data were included. Patients with extensive metastasized disease (>2 tumoral organs, peritoneal carcinomatosis) were excluded. Progression-free and overall survival (PFS/OS) were...

ea0020p195 | Endocrine tumours and neoplasia | ECE2009

Microalbuminuria and insulin resistance in nondiabetic acromegalic patients

Yalin Ayse Serap , Sancak Seda , Deyneli Oguzhan , Gunes Mutlu , Yavuz Dilek Gogas , Akalin Nefise Sema

Growth hormon (GH) counteracts the effects of insulin on glucose metabolism and GH excess may lead to insulin resistance (IR). Impaired glucose tolerance (IGT) and diabetes mellitus (DM) are frequently associated with acromegaly. Microalbuminuria (MAU) is a well established cardiovascular (CV) risk factor and a predictor of CV mortality in both diabetic and nondiabetic subjects.The aim of this preliminary study was to investigate the MAU levels as a mark...

ea0020p196 | Endocrine tumours and neoplasia | ECE2009

Safety of long-term combined therapy with somatostatin analogues and cabergoline (CAB) on cardiac valve in acromegaly: an echocardiography study

Auriemma Renata Simona , Galderisi Maurizio , Galdiero Mariano , Grasso Ludovica Francesca Stella , De Martino Maria Cristina , De Leo Monica , Colao Annamaria , Pivonello Rosario

The aim of the present study was to evaluate cardiac valve insufficiency prevalence after 12-month combined treatment with somatostatin analogues (SA) and CAB in acromegalic patients partially responsive to high-dose and long-term SA monotherapy. Twenty-four patients entered the study. A standard echocardiography was performed in all patients at diagnosis, after high-dose and long-term SA therapy and 12 months after CAB addition to SA to evaluate ejection fraction (EF) and mit...

ea0020p197 | Endocrine tumours and neoplasia | ECE2009

Incidence of benign and malignant neoplasms in acromegalic patients at a single institution

Baldys-Waligorska Agata , Golkowski Filip , Krzentowska Anna , Sokolowski Grzegorz , Hubalewska-Dydejczyk Alicja

Introduction: In acromegalic patients the incidence of benign and malignant neoplasms, appears to be higher than that in the standard population. Our aim was to evaluate the incidence of tumours in acromegalic patients treated at our Department.Materials and methods: Over the years 1983–2008, 101 acromegalic patients (mean age 51.8±15.4 years), were diagnosed and treated in our Department. Pituitary macroadenoma and microadenoma were stated in ...

ea0020p198 | Endocrine tumours and neoplasia | ECE2009

Gastric neuroendocrine tumors – new diagnostic and therapeutic approach

Hubalewska-Dydejczyk Alicja , Gilis-Januszewska Aleksandra , Sowa-Staszczak Anna , Pach Dorota , Trofimiuk Malgorzata , Tomaszczuk Monika , Kulig Jan

The incidence of gastric neuroendocrine tumors (GNT) is increasing, what can be explained by the increased detection caused by the common use of the endoscopy and the pervasive use of acid suppressive therapy leading to enterochromatofine like cells proliferation. There are numerous new diagnostic/therapeutic GNT methods in use like: EUS, SRS, somatostatin therapy and 90Y/177Lu-DOTA-TATE radiotherapy.Materials and methods: In 1998–2008 37 patients w...

ea0020p199 | Endocrine tumours and neoplasia | ECE2009

The German NET-registry: an audit on the diagnosis and therapy of neuroendocrine tumours

Plockinger Ursula , Kloppel Gunther , Lohmann Rudiger

Introduction: Clinical experience with neuroendocrine tumours (NET) is difficult to acquire because they are rare and heterogeneous. The impact of recently published guidelines on diagnosis and therapy of NET is not known. The German NET-Registry offers a unique possibility to analyse data on diagnostic/therapeutic performance in a wide range of institutions. This study posed three questions: who provides the care for patients with NET; do the diagnostic/therapeutic procedures...

ea0020p200 | Endocrine tumours and neoplasia | ECE2009

Adrenocortical carcinoma: results of surgical treatment and clinico-morphological prognostic factors

Pirogov Denis , Britvin Timur , Polyakova Galina , Bogatyrev Oleg

The aim of the study was analysis of long-term results of surgical treatment in patients with adrenocortical carcinoma as well as definition of prognostic factors.From 1998 to 2008, examination and treatment of 53 patients with adrenocortical carcinoma (31 women and 22 men, mean age 52.8 years) was carried out in our institute: 13 patients had Cushing syndrome, 1 – virilization, 2 – total adrenohypercortisolism, and 37 – nonfunctioning tum...

ea0020p201 | Endocrine tumours and neoplasia | ECE2009

Parathyroid cancer

Kotova Irina , Britvin Timur , Beloshitsky Mikhail , Kalinin Arian

From 1987 to 2008, 226 patients were operated on for primary hyperparathyroidism (pHPT). In 17 (men and women, aged 21–71 years) of them, parathyroid carcinoma (PC) was verified by histologic analysis. Mixed pHPT form was noted in 12 patients, visceropathic one – in 4, and asymptomatic – in 1. Hypercalcemia was revealed in 14 of 17 patients, and elevation of parathyroid hormone (PTH) level (426–1160 pg/ml) – in 12. In 5 patients operated on before 1990...

ea0020p202 | Endocrine tumours and neoplasia | ECE2009

A National survey of neuroendocrine lung tumors

Popovic Bojana , Isailovic Tatjana , Bozic Ivana , Macut Djuro , Ognjanovic Sanja , Petakov Milan , Elezovic Valentina , Damjanovic Svetozar

Neuroendocrine lung tumors represent approximately 20% of all lung tumors. They range from low-grade well-differentiated NETs and well-differentiated neuroendocrine carcinomas (typical and atypical carcinoids) to aggressive poorly differentiated small-cell and large-cell neuroendocrine carcinomas. They can develop different clinical syndromes due to ectopic hormone secretion.We analyzed 178 patients with neuroendocrine tumors (age range: 17–79 years...

ea0020p203 | Endocrine tumours and neoplasia | ECE2009

Efficacy and safety of 90Y-DOTATATE therapy in neuroendocrine tumours (NETs)

Sowa-Staszczak Anna , Hubalewska-Dydejczyk Alicja , Kunikowska Jolanta , Krolicki Leszek , Mikolajczak Renata , Pawlak Dariusz , Gilis-Januszewska Aleksandra , Trofimiuk Malgorzata , Stefanska Agnieszka

Therapy with labeled somatostatin analogues is the modern approach to patients with disseminated or unresectable NETs expressing somatostatin receptors (SSTR). Octreotate is the somatostatin analogue with high affinity to SSTR type 2, most commonly present in NETs. The aim of the study was to assess the efficacy and toxicity of peptide receptor radionuclide therapy (PRRT) with the use of 90Y labelled Tyr3-octreotate, (90Y-DOTATATE) in NETs....

ea0020p204 | Endocrine tumours and neoplasia | ECE2009

The variability of clinical presentation of multiple endocrine neoplasia syndrome type 1 as the reason of the underestimated diagnosis

Elwira Elwira , Hubalewska-Dydejczyk Alicja , Pach Dorota , Kuniarzz Sylwia , Tracz Marta

Introduction: Multiple endocrine neoplasia (MEN) is a rare disease. Apart from the well recognised MEN2 syndrome the MEN1 is less common diagnosed. The MEN1 gene is localised on the 11q13 chromosome and encodes menin. There is no simple definition of MEN1 syndrome because of heterogenous combination over 20 different endocrine and non-endocrine tumours. According to the Gubbio consensus, MEN1 is diagnosed by the occurrence of two of the three main MEN1-related endocrine tumour...

ea0020p205 | Endocrine tumours and neoplasia | ECE2009

Acromegaly in the Swedish pituitary register: background data and up to 10 years follow-up

Engstrom Britt Eden , Bramnert Margareta , Ekman Bertil , Hoybye Charlotte , Karlsson Anders , Mattsson Cecilia , Rosen Thord , Valdemarsson Stig , Werner Sigbritt

Background: The aim of the Swedish Pituitary Register – the Swedish Pituitary Study Group’s quality register – is to guarantee that all patients with pituitary tumours get equivalent diagnostic evaluation and treatment, as well as to evaluate given therapy. In this study, patients diagnosed with acromegaly from 1991 are described.Methods: Data from 557 patients (275 men/282 women), median age 51 years (range 4–87), with acromegaly wer...

ea0020p206 | Endocrine tumours and neoplasia | ECE2009

Percutaneous laser ablation for palliative treatment of neuroendocrine liver metastases

Nasoni Silvia , Pacella Claudio Maria , Bianchini Antonio , Bizzarri Giancarlo , Rossi Zaccaria , Papini Enrico , Misischi Irene , Grimaldi Franco

Background: Liver metastases occur in about 40–85% of patients with neuroendocrine tumours (NET). NET usually run a rather indolent course but the 5-year survival is about 40% in patients with liver metastases versus 75–99% in subjects free of hepatic lesions. The most effective management and timing of treatment for patients with surgically unresectable metastases remains still unsettled.Purpose: To evaluate the feasibility, safety, and clinic...

ea0020p207 | Endocrine tumours and neoplasia | ECE2009

The colonic polyps in the patients with acromegaly

Dreval Alexandr , Kamynina Tamara , Pokramovich Julia , Nechaeva Olga , Tereschenko Sergey , Banina Victoria

Aim: To evaluate the frequency and morpho-histological characteristics of the colonic polyps (CP) in acromegaly patients (pts).Materials and methods: We studied 53 pts (50 female, 3 men) aged 23–76 (median – 47) with active acromegaly. The mean disease duration was 10.7±4.3 years. Somatotropinoma was diagnosed in 51 pts and somatoprolactinoma in two. The activity of acromegal? was confirmed on the base of the clinical and hormonal data. Ba...

ea0020p208 | Endocrine tumours and neoplasia | ECE2009

Laboratory diagnosis of gastrinoma remains difficult

Ardill Joy , Armstrong Lee , McCance David , Johnston Brian

Before the use of potent acid suppressing drugs and in particular proton pump inhibiters (PPI), most patients with gastrinoma presented with Zollinger–Ellison syndrome and diagnosis was problematic in only a few. In recent years, the syndrome is rarely seen and gastrinoma patients present with less overt symptoms and hypergastrinaemia which may be mild. Increasingly patients present later.In the population, hypergastrinaemia most commonly occurs bec...

ea0020p209 | Endocrine tumours and neoplasia | ECE2009

R171Q MEN1 polymorphism in patients presenting with hyperparathyroidism

Zatelli Maria Chiara , Filieri Carlo , Tagliati Federico , Ambrosio Maria Rosaria , degli Uberti Ettore

The change of aminoacid Arginine (CGG) to Glutamine (CAG) at position 171 (R171Q) in the MEN1 gene has been occasionally reported in MEN1 carriers, but also in 1.4 to 5% subjects among the general population, therefore it is still unclear whether it might represent a polymorphism and/or it has a role in tumourigenesis. The aim of our study was to evaluate the presence of the R171Q polymorphism in patients with MEN1-related states presenting for MEN1 genetic screening. F...

ea0020p210 | Endocrine tumours and neoplasia | ECE2009

Recurrence in patients with pituitary nonfunctioning adenoma

De Paola Grazia , Buzoianu Roxana Elena , Bondanelli Marta , Trasforini Giorgio , Zatelli Maria Chiara , Laparelli Marcello , Cavazzini Luigi , Ambrosio Maria Rosaria , degli Uberti Ettore

Nonfunctioning adenomas (NFA) are 30% of all pituitary adenomas. Transphenoidal surgery is the first line therapy, but recurrences are frequent (12% al 69%). NFA treatment and follow-up are controversial. Aim of our study was to evaluate the recurrence prevalence and the factors associated with tumor aggressiveness in patients with NFA. We studied 30 patients that underwent surgery: 14 patients (group A, 7F, 3.92±12.48 years) with and 16 patients (group B, 6F, 56.5±1...

ea0020p211 | Endocrine tumours and neoplasia | ECE2009

Clinical feature and genetic testing in patients with multiple endocrine neoplasia syndrome type 2

Przybylik-Mazurek Elwira , Hubalewska-Dydejczyk1 Alicja , Pach Dorota , Kuzniarz Sylwia , Jarzab Barbara , Gubala Elzbieta , Pawlaczek Agnieszka , Oczko-Wojciechowska Malgorzata

Background: Multiple endocrine neoplasia syndrome type 2 (MEN2) is a rare disease characterised by inherence in each patient medullary thyroid carcinoma (MTC), pheochromocytoma and in type MEN 2a primary hyperparathyroidism, in type MEN2b marfanoid habitus and neurofibromas. Mutation in RET proto-oncogene at chromosome 10 is a molecular cause of MEN2 syndrome.Methods: Eighteeen patients with MEN2 syndrome were enrolled: (10 women and 8 men) mean age 22&#...

ea0020p212 | Endocrine tumours and neoplasia | ECE2009

Pancreatic neuroendocrine tumors: a national survey

Isailovic Tatjana , Popovic Bojana , Petakov Milan , Ognjanovic Sanja , Macut Djuro , Bozic Ivana , Elezovic Valentina , Da Svetozar

Pancreatic neuroendocrine tumors (PETs) occurs in approximately 1 per 100 000 people per year and account for only 1–2% of all pancreatic tumors. Most of them are hormonally active, while about 30% secrete no detectable hormons and are discovered due to a tumor mass effect.Material and methods: We analysed 178 patients with neuroendocrine tumors (NETs) treated at our department in the last five years. The diagnosis was made by pathohistological exam...

ea0020p213 | Endocrine tumours and neoplasia | ECE2009

Image-guided radioiodine therapy of HCC following AFP-promoter targeted in vivo sodium iodide symporter (NIS) gene transfer

Klutz Katrin , Willhauck Michael J , Wunderlich Nathalie , Zach Christian , Senekowitsch-Schmidtke Reingard , Anton Martina , Goke Burkhard , Spitzweg Christine

Due to limited treatment options the prognosis of patients with advanced hepatocellular cancer (HCC) has remained poor. We therefore examined the feasibility of radioiodine therapy of HCC after human sodium iodide symporter (hNIS) gene transfer, using the tumor-specific alpha-fetoprotein (AFP) promoter for transcriptional targeting. For this purpose NIS gene transfer was performed in vivo in human HCC cell (HepG2) xenografts, using replication-deficient adenoviral vecto...

ea0020p214 | Endocrine tumours and neoplasia | ECE2009

The retrospective analysis of the pheochromocytoma diagnostic procedures in patients after laparoscopic adrenalectomy

Hubalewska-Dydejczyk Alicja , Budzynski Andrzej , Buziak-Bereza Monika , Pach Dorota , Stochmal Ewa , Trofimiuk Malgorzata , Przybylik-Mazurek Elwira , Chrzan Robert , Karcz Danuta , Urbanik Andrzej

The pheochromocytoma (PH) diagnosis is often very difficult, particularly in asymptomatic or oligosymptomatic patients. Every subject with adrenal tumor should be screened for PH, although many factors may interfere with biochemical evaluation. The false positive testing for PH may result in unnecessary surgical treatment.Methods: Retrospective analysis of 45 patients after laparoscopic adrenalectomy due to suspicion of PH (based on biochemical testing) ...

ea0020p215 | Endocrine tumours and neoplasia | ECE2009

Neuroendocrine disorders of patients with pituitary tumours

Ismailov Said , Makhkamov Kozim , Powell Michael , Grossman Ashley , Khalimova Zamira , Urmanova Yulduz

Aim: Aim of research is to study special features of pituitary adenoma (PA).Materials and methods: Seventy-four operations on CST were performed. Outcomes of surgery in 66 patients with PA were analyzed. Age of patients at surgery was from 18 to 71 years. Mean age of patients – 44 years. Four patients (6%) had a corticotropinoma, 11 patients (17%) had somatotropinoma, 11 patients (17%) had prolactinoma and remaining 40 patients (60%) had non-functio...

ea0020p216 | Endocrine tumours and neoplasia | ECE2009

Insulinomas: experience of Coimbra’s University Hospital, Endocrinology Department

Santos Jacinta , Paiva Isabel , Martinho Mariana , Vieira Alexandra , Carvalheiro Manuela

Background: Insulinomas are rare neuroendocrine tumours (4 cases/million patients per year), representing an important cause of hyperinsulinemia. Usually are benign and sporadic, but can be part of multiple endocrine neoplasias. To establish the diagnosis it is essential to document inappropriately high levels of insulin during episodes of hypoglycaemia.Aim: Retrospective analysis of the clinical files of the patients followed in our department since Jan...

ea0020p217 | Endocrine tumours and neoplasia | ECE2009

The ectopic adrenocorticotropic hormone syndrome in carcinoid tumors (case report)

Gabidzashvili Nino , Vinogradskaya Olga , Zykova Polina , Pronin Vyatcheslav

Ectopic production of adrenocorticotropic hormone by carcinoid tumors is relatively uncommon. This report describes a woman who had Cushing syndrome from the ectopic secretion of adrenocorticotropic hormone by a carcinoid tumor. Before her hospitalization the patient’s conditions was misdiagnosed as disease of connective tissue and thus the patient was treated inadequately. The untreated hypercortisolism caused bilateral pneumonia and sepsis. There are three instructive e...

ea0020p218 | Endocrine tumours and neoplasia | ECE2009

Growth hormone deficiency problems in adult patients with pituitary adenomas

Urmanova Yulduz , Shakirova Mukhlisa

Aim of the research: To study neuroendocrine disorders at growth hormone deficiency (GHD) in adult patients with various pituitary tumours.Materials and methods: There 27 adult patients with GHD due to different sellar region neoplasms were evaluated in 2008. Among them, there were 20 women and 7 men. Average age of patients constituted 36.3 years.All patients evaluated with clinical, biochemical, hormonal, instrumental, roentgenol...

ea0020p219 | Endocrine tumours and neoplasia | ECE2009

Parathyroid surgery a paradigm shifts from inpatient to a day case surgery

Sinha Apurva , Siddiqui Afaq , Siddhan Raj , Kishore Makam , Parkinathan V

Introduction: There has been an increasing trend towards outpatient and short stay surgery in UK in last 20 years. This leads to reduced costs, reduced inpatient waiting lists, increased availability of inpatient beds and has the psychological benefit of avoiding prolonged hospitalisation.We liked to evaluate the feasibility of day case and short stay surgery for parathyroid disease in our district general hospital.Material and method: It was retrospecti...

ea0020p220 | Endocrine tumours and neoplasia | ECE2009

Oktreotid-depot therapy of acromegaly with long action somatostatin analogue

Pokramovich Julia , Dreval Alexandr , Nechaeva Olga , Pronin Viacheslav , Koloda Dmitry , Gitel Evgeny

Aim: To estimate efficiency of long acting somatostatin analog (Oktreotid-Depot, Ltd ‘FarmSyntez’, Russia) in acromegaly treatment.Material and methods: Twenty-five patients with the confirmed acromegaly diagnosis, active phase, receiving Oktreotid-Depot therapy within 6–12 months in a single dose of 20–40 mg/month. Every three months dynamics of clinical signs, basal IGF-1 and GH levels and pituitary adenoma size were analyzed.<p...

ea0020p221 | Endocrine tumours and neoplasia | ECE2009

Severe elevation of testosterone serum levels as unique finding in occult Sertoli-Leydig ovarian cell tumors

Paragliola Rosa Maria , Ricciato Maria Pia , Gallo Francesca , De Rosa Annapina , Senes Paola , Rota Carlo Antonio , Pontecorvi Alfredo , Corsello Salvatore Maria

Hirsutism affects 5–10% of women of reproductive age and may be the initial sign of an androgen disorder. We describe two cases of occult Sertoli-Leydig ovarian cell tumor suspected only on the basis of clinical and laboratory features.The first patient, a 42 year-old woman came to our attention for hirsutism. Several blood samples showed a very high testosterone concentration (~4 ng/ml), while non-ovarian causes of hyperandrogenism were excluded. A...

ea0020p222 | Endocrine tumours and neoplasia | ECE2009

Treatment of active acromegaly with the somatostatin analogue lanreotide SR

Mykytuyk Myroslava , Khyzhnyak Oksana , Karachentsev Yuriy

Background and aims: The long-acting somatostatin analogs represent are nowadays the first-line medical treatment of acromegaly. To assess the efficacy and tolerability of lanreotide-SR (LSR) in the treatment of active acromegaly.Subjects and methods: Eleven patients (2 men and 9 women; aged 27–75 years, median 47.4 years) were treated in whom active acromegaly with during disease from 1 to 34 years. All patients had the macroadenoma of hypophysis i...

ea0020p223 | Endocrine tumours and neoplasia | ECE2009

Should we offer combination scan in all patients with parathyroid disease: a district general hospital experience

Sinha Apurva , Siddiqui Afaq , Siddhan Raj , Kishore Makam , Parkinathan V

Introduction: Tc 99m sestamibi scan and ultrasound are been used most frequently than other imaging technique in the pre operative localization of parathyroid gland in primary hyperparathyroidism. We liked to evaluate our hospital experience with the scan in preoperative localization of the glandular disease.Method and material: It was a retrospective audit of 7 years from 2000–2007 of 48 patient who underwent open explorative procedure by single su...

ea0020p224 | Endocrine tumours and neoplasia | ECE2009

Lanreotide effects on glucose metabolism in evolutive acromegaly in remission during chemotherapy

Galoiu Simona , Purice Mariana , Hortopan Dan , Dumitrascu Anda , Coculescu Mihail

Lanreotide has long been used in the therapy of GH secreting pituitary adenomas and other somatostatin receptor positive neuroendocrine tumors.Aims: To determine the impact on glucose metabolism of the 6 months of lanreotide therapy, beside of the antisecretory and antiproliferative effects.Patients and methods: Seven patients with active acromegaly treated with lanreotide, admitted in the Department of Neuroendocrinology, Institut...